Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Kineta Inc.
Namida Lab
Revolution Medicines, Inc.
Imperial College London
Shanghai Fengxian District Central Hospital
University of Manchester
Shenzhen BinDeBio Ltd.
Quantgene Inc.
Mie University
Shenzhen Second People's Hospital
Rutgers, The State University of New Jersey
Instituto de Investigação em Imunologia